Tumor-Targeting Strategies with Anticancer Platinum Complexes

Drug Delivery in Oncology: From Basic Research to Cancer Therapy

Volumn 3, Issue , 2011, Pages 1605-1629

  Galanski, Markus ^a   Keppler, Bernhard K ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Anticancer properties; Drug delivery; Drug targeting; LipoPlatin ; LipOxal ; Platinum complex; ProLindac

Indexed keywords

EID: 84873734017     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527634057.ch49     Document Type: Chapter

References (48)

1. Rosenberg, B., VanCamp, L., and Krigas, T. (1965) Inhibition of cell division in Escherichia coli by electrolysis products from a platinum electrode. Nature, 205, 698-699.
2. Rosenberg, B. (1978) Platinum complexes for the treatment of cancer. Interdiscip. Sci. Rev., 3, 134-147.
3. Alderden, R.A., Hall, M.D., and Hambley, T.W. (2006) The discovery and development of cisplatin. J. Chem. Educ., 83, 728-734.
4. Rosenberg, B., VanCamp, L., Trosko, J.E., and Mansour, V.H. (1969) Platinum compounds: a new class of potent antitumour agents. Nature, 222, 385-386.
5. Jakupec, M.A., Galanski, M., and Keppler, B.K. (2003) Tumour-inhibiting platinum complexes - state of the art and future perspectives. Rev. Physiol. Biochem. Pharmacol., 146, 1-53.
6. O'Dwyer, P.J., Stevenson, J.P., and Johnson, S.W. (2000) Clinical pharmacokinetics and administration of established platinum drugs. Drugs, 59 (Suppl. 4), 19-27.
7. Galanski, M., Jakupec, M.A., and Keppler, B.K. (2005) Oxaliplatin and derivatives as anticancer drugs - novel deign strategies in Metal Compounds in Cancer Chemotherapy (eds J.M. Pérez, M.A. Fuertes and C. Alonso), Research Signpost, Trivandrum, pp. 155-185.
8. Wheate, N.J., Walker, S., Craig, G.E., and Oun, R. (2010) The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans., 39, 8113-8127.
9. Galanski, M. (2006) Recent developments in the field of anticancer platinum complexes. Recent Pat. Anticancer Drug Discov., 1, 285-295.
10. Galanski, M., Jakupec, M.A., and Keppler, B.K. (2005) Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches. Curr. Med. Chem., 12, 2075-2094.
11. Kelland, L. (2007) The resurgence of platinum-based cancer chemotherapy. Nat. Rev. Cancer, 7, 573-584.
12. Reedijk, J. (1999) Why does cisplatin reach guanine-N7 with competing S-donor ligands available in the cell? Chem. Rev., 99, 2499-2510.
13. Jakupec, M.A., Galanski, M., and Keppler, B.K. (2004) The effect of cytoprotective agents in platinum anticancer theraphy in Metal Complexes in Tumor Diagnosis and as Anticancer Agents, Metal Ions in Biological Systems, Vol. 42 (eds A. Sigel and H. Sigel), Dekker, New York, pp. 179-208.
14. Arnesano, F. and Natile, G. (2009) Mechanistic insight into the cellular uptake and processing of cisplatin 30 years after its approval by FDA. Coord. Chem. Rev., 253, 2070-2081.
15. Wang, D. and Lippard, S.J. (2005) Cellular processing of platinum anticancer drugs. Nat. Rev. Drug Discov., 4, 307-320.
16. Takahara, P.M., Rosenzweig, A.C., Frederick, C.A., and Lippard, S.J. (1995) Crystal structure of double-stranded DNA containing the major adduct of the anticancer drug cisplatin. Nature, 377, 649-652.
17. Dufrasne, F. and Galanski, M. (2007) The relation between stereochemistry and biological activity of platinum(II) complexes chelated with chiral diamine ligands: an intricate problem. Curr. Pharm. Des., 13, 2781-2794.
18. Hall, M.D., Mellor, H.R., Callaghan, R., and Hambley, T.W. (2007) Basis for design and development of platinum(IV)anticancer complexes. J. Med. Chem., 50, 3403-3411.
19. Top, S., Bachir Kaloun, E., Vessi'eres, A., Leclercq, G., Laïos, I., Ourevitch, M., Deuschel, C., McGlinchey, M.J., and Jaouen, G. (2003) Tamoxifen derivatives for delivery of the antitumoral (DACH)Pt group: selective synthesis by McMurry coupling, and biochemical behaviour. ChemBioChem, 4, 754-761.
20. Xia, W. and Low, P.S. (2010) Folate-targeted therapies for cancer. J. Med. Chem., 53, 6811-6824.
21. Aronov, O., Horowitz, A.T., Gabizon, A., and Gibson, D. (2003) Folate-targeted PEG as a potential carrier for carboplatin analogs. Synthesis and in vitro studies. Bioconjug. Chem., 14, 563-574.
22. Ohya, Y., Nagatomi, K., and Ouchi, T. (2001) Synthesis and cytotoxic activity of macromolecular prodrug of cisplatin using poly(ethylene glycol) with galactose residues or antennary galactose units. Macromol. Biosci., 1, 355-363.
23. Marin, J.J.G., Romero, M.R., Vallejo, M., and Monte, M.J. (2005) Targeting of cytostatic bile acid derivatives toward tumours of the enterohepatic circuit. Cancer Ther., 3, 57-64.
24. Dominguez, M.F., Macias, R.I.R., Izco-Basurko, I., de la Fuente, A., Pascual, M.J., Criado, J.M., Monte, M.J., Yajeya, J., and Marin, J.J.G. (2001) Low in vivo toxicity of a novel cisplatinursodeoxycholic derivative (Bamet-UD2) with enhanced cytostatic activity versus liver tumors. J. Pharmacol. Exp. Ther., 297, 1106-1112.
25. Briz, O., Angeles Serrano, M., Rebollo, N., Hagenbuch, B., Meier, P.J., Koepsell, H., and Marin, J.J.G. (2002) Carriers involved in targeting the cytostatic bile acid-cisplatin derivatives cis-diammine-chlorocholylglycinateplatinum( II) and cis-diamminebisursodeoxycholateplatinum( II) toward liver cells. Mol. Pharmacol., 61, 853-860.
26. Monte, M.J., Ballestero, M.R., Briz, O., Perez, M.J., and Marin, J.J.G. (2005) Proapoptotic effect on normal and tumor intestinal cells of cytostatic drugs with enterohepatic organotropism. J. Pharmacol. Exp. Ther., 315, 24-35.
27. Ott, I. and Gust, R. (2007) Preclinical and clinical studies on the use of platinum complexes for breast cancer treatment. Anticancer Agents Med. Chem., 7, 95-110.
28. Galanski, M. and Keppler, B.K. (2007) Searching for the magic bullet: anticancer platinum drugs which can be accumulated or activated in the tumor tissue. Anticancer Agents Med. Chem., 7, 55-73.
29. Gabano, E., Ravera, M., and Osella, D. (2009) The drug targeting and delivery approach applied to Pt-antitumour complexes. A coordination point of view. Curr. Med. Chem., 16, 4544-4580.
30. Harper, B.W., Krause-Heuer, A.M., Grant, M.P., Manohar, M., Garbutcheon-Singh, K.B., and Aldrich-Wright, J.R. (2010) Advances in platinum chemotherapeutics. Chem. Eur. J., 16, 7064-7077.
31. Klenner, T., Wingen, F., Keppler, B.K., Krempien, B., and Schmaehl, D. (1990) Anticancer-agent-linked phosphonates with antiosteolytic and antineoplastic properties: a promising perspective in the treatment of bone-related malignancies? J. Cancer Res. Clin. Oncol., 116, 341-350.
32. Klenner, T., Valenzuela-Paz, P., Amelung, F., Muench, H., Zahn, H., Keppler, B.K., and Blum, H. (1993) Platinum phosphonato complexes with particular activity bone malignancies. Evaluation of an experimental tumor model highly predictive for the clinical situation in Metal Complexes in Cancer Chemotherapy, (ed. B.K. Keppler), Wiley-VCH Verlag GmbH, Weinheim, pp. 85-127.
33. Galanski, M., Slaby, S., Jakupec, M.A., and Keppler, B.K. (2003) Synthesis, characterization and in vitro antitumor activity of osteotropic diam(m)ineplatinum(II) complexes bearing a N, N'-bis(phosphonomethyl)glycine ligand. J. Med. Chem., 46, 4946-4951.
34. Matsumura, Y. and Maeda, H.A. (1986) New concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res., 46, 6387-6392.
35. ™: a successful liposomal formulation of cisplatin. Expert Opin. Investig. Drugs, 18, 1197-1218.
36. Boulikas, T., Pantos, A., Bellis, E., and Christofis, P. (2007) Designing platinum compounds in cancer: structures and mechanisms. Cancer Ther., 5, 537-583.
37. Regulon (2009) LipoPlatin as a Trojan Horse for Cancer: Evidence that LipoPlatin Nanoparticles Fuse with, and Enter also by Phagocytosis through, the Cell Membrane [Press Release], Regulon, Mountain View, CA.
38. Devarajan, P., Tarabishi, R., Mishra, J., Ma, Q., Kourvetaris, A., Vougiouka, M., and Boulikas, T. (2004) Low renal toxicity of Lipoplatin compared to cisplatin in animals. Anticancer Res., 24, 2193-2200.
39. ™ as a chemotherapy and antiangiogenesis drug. Cancer Ther., 5, 349-376.
40. Rihova, B. (2007) Biocompatibility and immunocompatibility of water-soluble polymers based on HPMA. Composites B, 38, 386-397.
41. Nowotnik, D.P. and Cvitkovic, E. (2009) ProLindac (AP5346): a review of the development of an HPMA DACH platinum polymer therapeutic. Adv. Drug Deliv. Rev., 61, 1214-1219.
42. Sood, P., Bruce Thurmond, K., Jacob, J.E., Waller, L.K., Silva, G.O., Stewart, D.R., and Nowotnik, D.P. II (2006) Synthesis and characterization of AP5346, a novel polymer-linked diaminocyclohexyl platinum chemotherapeutic agent. Bioconjug. Chem., 17, 1270-1279.
43. Rice, J.R., Gerberich, J.L., Nowotnik, D.P., and Howell, S.B. (2006) Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system. Clin. Cancer Res., 12, 2248-2254.
44. Boulikas, T., Stathopoulos, G.P., Volakakis, N., and Vougiouka, M. (2005) Systemic lipoplatin infusion results in preferential tumor uptake in human studies. Anticancer Res., 25, 3031-3039.
45. Froudarakis, M.E., Pataka, A., Pappas, P., Anevlavis, S., Argiana, E., Nikolaidou, M., Kouliatis, G., Pozova, S., Marselos, M., and Bouros, D. (2008) Phase 1 trial of lipoplatin and gemcitabine as a second-line chemotherapy in patients with nonsmall cell lung carcinoma. Cancer, 113, 2752-2760.
46. Koukourakis, M.I., Giatromanolaki, A., Pitiakoudis, M., Kouklakis, G., Tsoutsou, P., Abatzoglou, I., Panteliadou, M., Sismanidou, K., Sivridis, E., and Boulikas, T. (2010) Concurrent liposomal cisplatin (Lipoplatin), 5-fluorouracil and radiotherapy for the treatment of locally advanced gastric cancer: a phase I/II study. Int. J. Radiat Oncol. Biol. Phys., 78, 150-155.
47. Stathopoulos, G.P., Boulikas, T., Kourvetaris, A., and Stathopoulos, J. (2006) Liposomal oxaliplatin in the treatment of advanced cancer: a phase I study. Anticancer Res., 26, 1489-1493.
48. Campone, M., Rademaker-Lakhai, J.M., Bennouna, J., Howell, S.B., Nowotnik, D.P., Beijnen, J.H., and Schellens, J.H.M. (2007) Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients. Cancer Chemother. Pharmacol., 60, 523-533.